Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 669 across all filing types
Latest filing 2025-01-21 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
奥锐特药业股份有限公司第三届董事会第十二次会议决议公告
Transaction in Own Shares Classification · 100% confidence The document is a formal announcement of a board meeting resolution by 奥锐特药业股份有限公司. It details the approval of a share repurchase plan, including the amount, price limit, and timeframe. The document is not a full financial report but an announcement of a corporate action (share buyback). It references another announcement on the stock exchange website for more details. The document length is short (847 characters), and it is clearly an announcement of a capital action rather than the action itself or a detailed report. Therefore, it fits best under the category 'Transaction in Own Shares' (POS).
2025-01-21 Chinese
奥锐特药业股份有限公司关于公司董事长提议公司回购股份的提示性公告
Transaction in Own Shares Classification · 95% confidence The document is a company announcement regarding a proposal by the chairman to repurchase company shares. It details the proposal's background, purpose, method, price limits, funding source, and timeline. It is not a financial report, earnings release, or regulatory certification. The document is an announcement of a share repurchase plan, which fits the category of 'Transaction in Own Shares' (POS). The document length is short (1330 characters), but it contains substantive information about the share repurchase proposal, not just a notice of report publication or a certification. Therefore, the appropriate classification is POS with high confidence.
2025-01-21 Chinese
奥锐特药业股份有限公司关于以集中竞价交易方式回购股份方案的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement by 奥锐特药业股份有限公司 regarding a share repurchase plan through centralized bidding on the Shanghai Stock Exchange. It details the amount, price limits, purpose (conversion of convertible bonds), authorization, risks, and procedural aspects of the share buyback. The document is not a financial report, earnings release, or management discussion but a formal disclosure of a capital action (share repurchase). It does not contain financial statements or earnings data but focuses on the company's capital structure change via share buyback. According to the filing definitions, announcements about share repurchases fall under 'Transaction in Own Shares' (POS). The document length and content confirm it is the actual announcement of the repurchase plan, not a brief notice or a report publication announcement. Therefore, the correct classification is POS with high confidence.
2025-01-21 Chinese
奥锐特药业股份有限公司关于使用部分闲置募集资金进行现金管理到期赎回公告
Capital/Financing Update Classification · 95% confidence The document is a company announcement regarding the use of idle raised funds for cash management and the redemption of a structured deposit product. It includes details of board approval, amounts involved, and dates. The document is short (838 characters) and primarily informs about a specific financial activity related to the company's capital management. It does not contain comprehensive financial statements, audit information, or detailed financial results. It is not a report itself but an announcement of a financing-related activity involving the use of raised funds. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2025-01-13 Chinese
奥锐特药业股份有限公司关于变更持续督导保荐代表人的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the change of the continuous supervision sponsor representative for a convertible bond issuance project by the company 奥锐特药业股份有限公司. It details the replacement of one sponsor representative with another and confirms that this change does not affect the previously issued opinions or documents. The document is short (945 characters) and focuses on management and sponsor representative changes related to a financing project, but it does not contain financial statements or detailed financial data. It is not a full report, earnings release, or regulatory certification. The content fits best under a Capital/Financing Update as it relates to ongoing supervision of a convertible bond issuance and changes in the sponsor representatives responsible for that financing activity.
2025-01-09 Chinese
奥锐特药业股份有限公司关于部分募集资金投资项目延期的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 奥锐特药业股份有限公司 regarding the delay of a specific fundraising investment project related to the construction of a production line. It details the postponement of the project completion date, the use and management of the raised funds, and the company's board and supervisory approvals. The document does not contain financial statements or detailed financial performance data but focuses on the update about the capital investment project and its timeline. This fits the category of a Capital/Financing Update (CAP) as it provides updates on the company's fundraising and capital usage status, specifically about the investment project funded by convertible bonds.
2024-12-30 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.